Trial reportNature medicine2021
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
2 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 197 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
197citing papers in PubMed, 6 pooled it
21.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients
Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)
Who cites it
197 citing papers in PubMed, 6 syntheses or guidelines pooled it, 325 citations in OpenAlex.
- Pooled it
- Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Guideline
- Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of diffuse pleural mesothelioma: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.Journal for immunotherapy of cancer · 2023Guideline
- Neoadjuvant treatment for stage III and IV cutaneous melanoma.The Cochrane database of systematic reviews · 2023Pooled it
- Outcomes After Curative Metastasectomy for Patients with Malignant Melanoma: A Systematic Review and Meta-analysis.Annals of surgical oncology · 2022Pooled it
- Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.Nature medicine · 2026Trial
- Trial
- Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.Nature medicine · 2025Trial
- Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysis.Clinical and translational medicine · 2025Trial
- Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Cancer cell · 2024Trial
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.Nature medicine · 2024Trial
- Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.British journal of cancer · 2024Trial
- Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFNature medicine · 2024Trial
- Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study.Nature communications · 2024Trial
- Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.Clinical and translational medicine · 2024Trial
- Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.Nature medicine · 2024Trial
- IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.The Journal of experimental medicine · 2023Trial
- Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.Journal for immunotherapy of cancer · 2022Trial
137 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
34 authors at 3 institutions in 3 countries.
E A RozemanDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
E P Hoefsmit *Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-3989-8175
I L M Reijers *Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
R P M SawMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-3354-806X
J M VersluisDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
O KrijgsmanDepartment of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
P DimitriadisDepartment of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-3546-285X
K SikorskaDepartment of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
B A van de WielDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
H ErikssonDepartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
M GonzalezMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
A Torres AcostaDepartment of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
L G Grijpink-OngeringDepartment of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
K ShannonMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8538-3132
J B A G HaanenDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-5884-7704
J StretchMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
S Ch'ngMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
O E NiewegMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0003-2997-6413
H A MalloDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
S AdriaanszDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
R M KerkhovenGenomics Core Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands.
S CornelissenCore Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands.
A BroeksCore Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands.
W M C KlopDepartment of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
C L ZuurDepartment of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
W J van HoudtDepartment of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
D S PeeperDepartment of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-1293-3177
A J SpillaneMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-9520-0181
A C J van AkkooiDepartment of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
R A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-8991-0013
T N M SchumacherDepartment of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-0517-8804
A M MenziesMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
G V LongMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
C U BlankDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. c.blank@nki.nl.ORCID http://orcid.org/0000-0002-7945-5846
The Netherlands Cancer Institute · NLThe University of Sydney · AUKarolinska University Hospital · SE
Funding
Bristol-Myers Squibb (Bristol-Myers Squibb Company) CA209-278Bristol-Myers Squibb (Bristol-Myers Squibb Company) CA209-701
Abstract
Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN ( NCT02437279 ) and phase 2 OpACIN-neo ( NCT02977052 ) studies
Indexed as
AdultAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiomarkers, TumorCTLA-4 AntigenDisease-Free SurvivalFemaleHumansImmunotherapyInterferon-gammaIpilimumabMaleMelanomaMiddle AgedMutationNeoadjuvant TherapyB7-H1 AntigenBiomarkers, TumorCTLA-4 AntigenIFNG protein, humanInterferon-gammaIpilimumabNivolumab
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT02437279ClinicalTrials.gov
NCT02977052ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.